Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xi'an Key Laboratory of Hematological Diseases, Xi'an, Shaanxi, China.
Front Immunol. 2024 Jun 28;15:1414264. doi: 10.3389/fimmu.2024.1414264. eCollection 2024.
Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, demonstrably improving patient outcomes and prognosis. However, its application has introduced new challenges, such as safety concerns, off-target toxicities, and significant costs. Natural killer (NK) cells are crucial components of the innate immune system, capable of eliminating tumor cells without prior exposure to specific antigens or pre-activation. This inherent advantage complements the limitations of T cells, making CAR-NK cell therapy a promising avenue for hematological tumor immunotherapy. In recent years, preclinical and clinical studies have yielded preliminary evidence supporting the safety and efficacy of CAR-NK cell therapy in hematological malignancies, paving the way for future advancements in immunotherapy. This review aims to succinctly discuss the characteristics, significant therapeutic progress, and potential challenges associated with CAR-NK cell therapy.
嵌合抗原受体 T（CAR-T）细胞疗法彻底改变了血液系统恶性肿瘤的治疗方法，显著改善了患者的预后。然而，其应用带来了新的挑战，如安全性问题、脱靶毒性和高昂的成本。自然杀伤（NK）细胞是先天免疫系统的关键组成部分，能够在不预先暴露于特定抗原或预先激活的情况下消除肿瘤细胞。这种固有优势弥补了 T 细胞的局限性，使 CAR-NK 细胞疗法成为血液系统肿瘤免疫治疗的一个有前途的途径。近年来，临床前和临床研究提供了初步证据，支持 CAR-NK 细胞疗法在血液系统恶性肿瘤中的安全性和有效性，为免疫治疗的未来发展铺平了道路。本综述旨在简要讨论 CAR-NK 细胞疗法的特点、重大治疗进展和潜在挑战。
